R M Freidinger

发表

Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog.

D. Veber, R. Freidinger, R Saperstein, 1980, Science.

Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide.

J J Baldwin, M. Sanguinetti, R. Freidinger, 1997, Journal of medicinal chemistry.

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

S Vickers, R. Freidinger, D. Reiss, 1998, Journal of medicinal chemistry.

Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2.

B H Arison, R G Smith, D. Underwood, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Novel glutamic acid derived cholecystokinin receptor ligands.

R. Freidinger, W. L. Whitter, R. Chang, 1990, Journal of medicinal chemistry.

Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.

B. E. Evans, M A Jacobson, M. Bock, 1999, Bioorganic & medicinal chemistry letters.

Non-peptide ligands for peptide receptors.

R. Freidinger, R M Freidinger, 1989, Trends in pharmacological sciences.

Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.

M. Bock, R. Freidinger, J. Vacca, 1997, Journal of medicinal chemistry.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1988, Journal of medicinal chemistry.

Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.

R M Freidinger, D S Perlow, M T Guidotti, 1998, Bioorganic & medicinal chemistry letters.

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

D. Veber, R. Freidinger, D. Reiss, 1995, Journal of medicinal chemistry.

Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

B. E. Evans, D. Veber, K. Rittle, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Nonpeptidic ligands for peptide and protein receptors.

R. Freidinger, R M Freidinger, 1999, Current opinion in chemical biology.

Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.

B. E. Evans, K. Rittle, M. Bock, 1989, Journal of medicinal chemistry.